

235/030

Payment Advice



CHRONIC AIRWAY
THERAPEUTICS

All Registry communications to:

C/- Link Market Services Limited
Locked Bag A14, Sydney South, NSW, 1235
Telephone: 1300 554 474
Issuer Code: CATU
Email: registrars@linkmarketservices.com.au
Website: www.linkmarketservices.com.au

CHRONIC AIRWAY THERAPEUTICS LIMITED

ABN: 35 628 608 113

ASHMORE ENTERPRISES PTY LTD <C & V HOOD SUPER FUND
A/C>
38 REED ST
ASHMORE QLD
4214

**CAPITAL REPAYMENT
STATEMENT**

Reference No.: I*****5819
Payment Date: 31 January 2020
Record Date: 21 January 2020

Security Description	Rate per Security	Participating Holding	Capital Amount
CATU - FULLY PAID ORDINARY SHARES	\$0.000146	62,313	\$9.10
		Less Withholding Tax	\$0.00
		Net Amount	AUD 9.10
		Represented By:	
		Cheque amount	AUD 9.10

CHEQUE

The amount of AUD 9.10 was paid by cheque number 1792

Sold in 2019 FY.



WealthHub Securities Limited
ABN 83 089 718 249
AFSL No. 23 0704

GPO Box 4545 Telephone 13 13 80
Melbourne nabtrade.com.au
VIC 3001

Sell confirmation

C & V HOOD SUPERANNUATION FUND
38 REED ST
ASHMORE QLD 4214

Trade date: 28/06/2019
As at date: 28/06/2019
Settlement date: 02/07/2019
Confirmation number: 50640928
Account number: NT1707488-002
Exchange: ASX/Chi-X*
Registration type: Broker Sponsored
HIN: 0069594522

Registration Details:
ASHMORE ENTERPRISES PTY LTD
<C & V HOOD SUPER FUND A/C>,
38 REED ST
ASHMORE QLD 4214

Tax invoice - please retain for tax purposes.

We have sold for you:				
Quantity	Code	Security Description	Average price per share	Consideration
62,313	IVX.ASX	INVION LIMITED ORDINARY FULLY PAID	\$0.0150	\$934.70
		Brokerage		\$14.95
		includes GST		\$1.36
		Total amount receivable		\$919.75

Contributing trades:				
Conf number	Total quantity	Price	Basis of quotation	Condition Code
50640928	62,313	\$0.0150		

If this confirmation does not correspond with your records please contact us within 48 hours, on 13 13 80 between 8am and 8pm (AEST), Monday to Friday.

Settlement instructions

All securities must be received by 9am AEST on the above settlement date. This transaction will be settled in accordance with your instructions as follows.

80765AD311

* WealthHub Securities is a Market Participant of both the Australian Securities Exchange Limited (ASX) and Chi-X Australia Pty Ltd (Chi-X). As such, your transaction may have been executed on one or both of these exchanges.

The nabtrade service (nabtrade) is provided by WealthHub Securities Limited ABN 83 089 718 249, AFSL No. 230704 (WealthHub Securities). WealthHub Securities is a Market Participant under the ASIC Market Integrity Rules and a wholly owned subsidiary of National Australia Bank Limited ABN 12 004 044 937, AFSL No. 230686 (NAB). NAB doesn't guarantee its subsidiaries' obligations or performance, or the products or services its subsidiaries offer. © National Australia Bank Limited

SPIN OUT OF RESPIRATORY ASSETS AND CHRONIC AIRWAY THERAPEUTICS LIMITED

SHAREHOLDER Q&A

Melbourne, Australia, 21 February 2019: Invion Limited (ASX:IVX) (Company or Invion) provides this Q&A further to its recent confirmation of the spin-out of its respiratory assets and the transfer Invion's shares in Chronic Airway Therapeutics Limited (CAT) to the shareholders of Invion by way of an equal capital reduction. The Q&A has been prepared to address questions that the Company has received.

1. Has the ATO ruling mentioned in the NOM for the EGM been released?

Yes, the ATO published its ruling following shareholder approval of the transaction and the completion of the transaction. Class Ruling CR 2019/13 is available here:

<https://www.ato.gov.au/law/view/view.htm?docid=%22CLR%2FCR201913%2FNAT%2FATO%2F00001%22>.

Invion recommends you download the PDF of CR 2019/13 (available here: <https://www.ato.gov.au/law/view/pdf/pbr/cr2019-013.pdf>) for your records.

2. Are there any public reports, financial information or list of directors?

As a public, unlisted company, CAT will lodge audited annual financial statements with ASIC and will maintain its corporate information in accordance with the reporting requirements of the *Corporations Act 2001* (Cth). The Directors of CAT (as at the date of this Q&A) are detailed in pages 16-18 of the Notice of Meeting: <https://www.asx.com.au/asxpdf/20181221/pdf/441frb74jx5v0r.pdf>. Once CAT's website is launched (see below) the website will contain additional information for CAT shareholders.

3. What is the cost base for the CAT shares?

In accordance with paragraph 28 of the Class Ruling 2019/13, the cost base for CAT shares is equal to \$0.0003159, being the market value of each CAT share worked out as at the time of their acquisition. An example is shown below, based on an example cost base of \$0.01 per Invion share. Invion recommends you discuss and confirm your cost base of shares, and the potential capital gains tax consequences, with your tax advisor.

- Cost base per Invion share at 11 February 2019 = \$0.01
- Capital reduction (market value of each CAT share) = \$0.0003159
- Reduced cost base per Invion share = \$0.0096841

- Cost base per CAT share = \$0.0003159

4. Are there any plans for a share buyback or listing on an exchange?

There are currently no plans for a share buyback or for listing CAT on any exchange.

5. How will I find out what is happening with CAT in the future?

CAT's website www.chronic-airway-therapeutics.com is currently under development. Once launched, the website will host investor information, corporate presentations, and financial reports. It is anticipated CAT's website will have a facility to enable shareholders to subscribe for updates. CAT's contact details are also listed below.